Management of Anticoagulation in Thrombocytopenic Patients

Clinical Decision Framework

Full therapeutic anticoagulation without platelet transfusion is recommended for patients with platelet counts ≥50 × 10⁹/L, according to the International Society on Thrombosis and Haemostasis 1
The American Society of Hematology recommends continuing full therapeutic anticoagulation without modification when the platelet count is above 50 × 10⁹/L, as this is well above the safety threshold established for anticoagulation in thrombocytopenic patients 1
For patients with platelet counts between 25-50 × 10⁹/L, the European Hematology Association suggests considering dose reduction strategies or switching to low molecular weight heparin (LMWH) at modified doses, particularly for lower-risk thrombotic events 1
The International Society on Thrombosis and Haemostasis recommends withholding anticoagulation unless dealing with acute high-risk thrombosis (proximal DVT, symptomatic PE) where platelet transfusion support may be considered for patients with platelet counts <25 × 10⁹/L 1

The European Renal Association notes that rivaroxaban is renally cleared, and dose adjustment may be needed for renal dysfunction independent of platelet count 2